Clin Endosc.  2022 Sep;55(5):581-587. 10.5946/ce.2021.283.

New sedatives and analgesic drugs for gastrointestinal endoscopic procedures

• Lee JM
• Park Y
• Park JM
• Park HJ
• Bae JY
• Seo SY
• Lee JH
• Chon HK
• Chung JW
• Choi HH
• Lee JK
• Kim BW
• Endoscopic Sedation Committee of the Korean Society of Gastrointestinal Endoscopy

• KMID: 2533295
• DOI: http://doi.org/10.5946/ce.2021.283

Abstract

Procedural sedation has become increasingly common in endoscopy. Sedatives and analgesics induce anxiolysis and amnesia. In addition, an appropriate level of sedation is necessary for safe procedures including therapeutic endoscopy. Midazolam and propofol are the most commonly used drugs in sedative endoscopy. In recent years, the need to ascertain the safety and effectiveness of sedation has increased in practice. Therefore, new sedatives and analgesic drugs for optimal sedative endoscopy, have recently emerged. This article reviews the characteristics of sedatives and analgesics, and describes their clinical use in gastrointestinal endoscopy.

Keyword

Analgesics; Conscious sedation; Endoscopy; Hypnotics and sedatives

Reference

1. Conscious Sedation TFT Committee of KSGE. A guidebook on sedation for gastrointestinal endoscopy. Seoul: Medbook;2015.

2. Training Committee. American Society for Gastrointestinal Endoscopy. Training guideline for use of propofol in gastrointestinal endoscopy. Gastrointest Endosc. 2004; 60:167–172.

3. Waring JP, Baron TH, Hirota WK, et al. Guidelines for conscious sedation and monitoring during gastrointestinal endoscopy. Gastrointest Endosc. 2003; 58:317–322.

4. Goudra BG, Singh PM. Propofol alternatives in gastrointestinal endoscopy anesthesia. Saudi J Anaesth. 2014; 8:540–545.

5. Goudra B, Gouda G, Mohinder P. Recent developments in drugs for GI endoscopy sedation. Dig Dis Sci. 2020; 65:2781–2788.

6. Forman SA. Clinical and molecular pharmacology of etomidate. Anesthesiology. 2011; 114:695–707.

7. Han SJ, Lee TH, Yang JK, et al. Etomidate sedation for advanced endoscopic procedures. Dig Dis Sci. 2019; 64:144–151.

8. Lee JM, Min G, Lee JM, et al. Efficacy and safety of etomidate-midazolam for screening colonoscopy in the elderly: a prospective double-blinded randomized controlled study. Medicine (Baltimore). 2018; 97:e10635.

9. Zhou X, Li BX, Chen LM, et al. Etomidate plus propofol versus propofol alone for sedation during gastroscopy: a randomized prospective clinical trial. Surg Endosc. 2016; 30:5108–5116.

10. Chen L, Liang X, Tan X, et al. Safety and efficacy of combined use of propofol and etomidate for sedation during gastroscopy: systematic review and meta-analysis. Medicine (Baltimore). 2019; 98:e15712.

11. Kim JH, Byun S, Choi YJ, et al. Efficacy and safety of etomidate in comparison with propofol or midazolam as sedative for upper gastrointestinal endoscopy. Clin Endosc. 2020; 53:555–561.

12. Scheinin H, Aantaa R, Anttila M, et al. Reversal of the sedative and sympatholytic effects of dexmedetomidine with a specific alpha2-adrenoceptor antagonist atipamezole: a pharmacodynamic and kinetic study in healthy volunteers. Anesthesiology. 1998; 89:574–584.

13. Liu W, Yu W, Yu H, et al. Comparison of clinical efficacy and safety between dexmedetomidine and propofol among patients undergoing gastrointestinal endoscopy: a meta-analysis. J Int Med Res. 2021; 49:3000605211032786.

14. Chen YT, Sun CK, Wu KY, et al. The use of propofol versus dexmedetomidine for patients receiving drug-induced sleep endoscopy: a meta-analysis of randomized controlled trials. J Clin Med. 2021; 10:1585.

15. Nishizawa T, Suzuki H, Hosoe N, et al. Dexmedetomidine vs propofol for gastrointestinal endoscopy: a meta-analysis. United European Gastroenterol J. 2017; 5:1037–1045.

16. Nishizawa T, Suzuki H, Sagara S, et al. Dexmedetomidine versus midazolam for gastrointestinal endoscopy: a meta-analysis. Dig Endosc. 2015; 27:8–15.

17. Belleville JP, Ward DS, Bloor BC, et al. Effects of intravenous dexmedetomidine in humans. I. Sedation, ventilation, and metabolic rate. Anesthesiology. 1992; 77:1125–1133.

18. Hall JE, Uhrich TD, Barney JA, et al. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg. 2000; 90:699–705.

19. Jalowiecki P, Rudner R, Gonciarz M, et al. Sole use of dexmedetomidine has limited utility for conscious sedation during outpatient colonoscopy. Anesthesiology. 2005; 103:269–273.

20. Zhang F, Sun HR, Zheng ZB, et al. Dexmedetomidine versus midazolam for sedation during endoscopy: a meta-analysis. Exp Ther Med. 2016; 11:2519–2524.

21. Kilpatrick GJ, McIntyre MS, Cox RF, et al. CNS 7056: a novel ultra-short-acting benzodiazepine. Anesthesiology. 2007; 107:60–66.

22. Goudra BG, Singh PM. Remimazolam: the future of its sedative potential. Saudi J Anaesth. 2014; 8:388–991.

23. Borkett KM, Riff DS, Schwartz HI, et al. A phase IIa, randomized, double-blind study of remimazolam (CNS 7056) versus midazolam for sedation in upper gastrointestinal endoscopy. Anesth Analg. 2015; 120:771–780.

24. Chen SH, Yuan TM, Zhang J, et al. Remimazolam tosilate in upper gastrointestinal endoscopy: a multicenter, randomized, non-inferiority, phase III trial. J Gastroenterol Hepatol. 2021; 36:474–481.

25. Zhu X, Wang H, Yuan S, et al. Efficacy and safety of remimazolam in endoscopic sedation-a systematic review and meta-analysis. Front Med (Lausanne). 2021; 8:655042.

26. Jhuang BJ, Yeh BH, Huang YT, et al. Efficacy and safety of remimazolam for procedural sedation: a meta-analysis of randomized controlled trials with trial sequential analysis. Front Med (Lausanne). 2021; 8:641866.

27. Domino EF, Chodoff P, Corssen G. Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. Clin Pharmacol Ther. 1965; 6:279–291.

28. Cohen LB, Delegge MH, Aisenberg J, et al. AGA institute review of endoscopic sedation. Gastroenterology. 2007; 133:675–701.

29. Akbulut UE, Saylan S, Sengu B, et al. A comparison of sedation with midazolam-ketamine versus propofol-fentanyl during endoscopy in children: a randomized trial. Eur J Gastroenterol Hepatol. 2017; 29:112–118.

30. Eskander AE, Baroudy NR, Refay AS. Ketamine sedation in gastrointestinal endoscopy in children. Open Access Maced J Med Sci. 2016; 4:392–396.

31. Lee YM, Kang B, Kim YB, et al. Procedural sedation for pediatric upper gastrointestinal endoscopy in Korea. J Korean Med Sci. 2021; 36:e136.

32. Fechner J, Ihmsen H, Jeleazcov C, et al. Fospropofol disodium, a water-soluble prodrug of the intravenous anesthetic propofol (2,6-diisopropylphenol). Expert Opin Investig Drugs. 2009; 18:1565–1571.

33. Cohen LB. Clinical trial: a dose-response study of fospropofol disodium for moderate sedation during colonoscopy. Aliment Pharmacol Ther. 2008; 27:597–608.

34. Toklu S, Iyilikci L, Gonen C, et al. Comparison of etomidate-remifentanil and propofol-remifentanil sedation in patients scheduled for colonoscopy. Eur J Anaesthesiol. 2009; 26:370–376.

35. Mandel JE, Tanner JW, Lichtenstein GR, et al. A randomized, controlled, double-blind trial of patient-controlled sedation with propofol/remifentanil versus midazolam/fentanyl for colonoscopy. Anesth Analg. 2008; 106:434–439.

36. Fossler MJ, Sadler BM, Farrell C, et al. Oliceridine (TRV130), a novel G protein-biased ligand at the μ-opioid receptor, demonstrates a predictable relationship between plasma concentrations and pain relief. I: development of a pharmacokinetic/pharmacodynamic model. J Clin Pharmacol. 2018; 58:750–761.

37. Food and Drug Administration (FDA). FDA approved drug products: Olinvyk (Oliceridine) injection [Internet]. Silver Spring (MD): FDA;2020. [cited 2022 Jan 17]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210730s000lbl.pdf.

38. Singla N, Minkowitz HS, Soergel DG, et al. A randomized, phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (μ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty. J Pain Res. 2017; 10:2413–2424.

39. Liang DY, Li WW, Nwaneshiudu C, et al. Pharmacological characters of oliceridine, a μ-opioid receptor G-protein-biased ligand in mice. Anesth Analg. 2019; 129:1414–1421.